Preliminary positive results for Phase I - II trial of Tesaro's Zejula with Keytruda in platinum-resistant ovarian cancer

March 26, 2018

Preliminary results for the TOPACIO trial (a Phase I/II trial) of Tesoro’s Zejula (niraparib) with Keytruda in women with platinum-resistant ovarian cancer were presented today at the 2018 Society of Gynecologic Oncology Annual Meeting.

In those women in the trial without the BRCA genetic mutation, there was a 26% response rate for the Zejula/Keytruda combination. According to Dr. Ursula A. Matulonis, MD, director, Gynecologic Oncology, Dana-Farber Cancer Institute, professor of medicine, Harvard Medical School, this is an important result, as single therapeutics in this population normally garner a response rate under 10%. In the trial members with the BRCA mutation, the response rate was 29%. 

The TOPACIO trial is also studying the use of Zejula/Keytruda in those patients with advanced metastatic triple-negative breast cancer. 

CP Wire

Submit an article to cafepharma's CP Wire. Click here to find out more.

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.